Ten Years of Experience with Biphasic Insulin Aspart 30: From Drug Development to the Latest Clinical Findings

Biphasic insulin aspart 30 (BIAsp 30) includes 30% soluble rapid-acting insulin aspart (IAsp) along with an intermediate-acting 70% protaminated IAsp that provides coverage of prandial and basal insulin in a single injection. As BIAsp 30 has been available internationally for 10 years, this review p...

Descripción completa

Detalles Bibliográficos
Autores principales: Liebl, Andreas, Prusty, Vinay, Valensi, Paul, Kawamori, Ryuzo, Christiansen, Jens Sandahl, Palmer, Andrew J., Balschmidt, Per, Ligthelm, Robert, Mohan, Viswanathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590411/
https://www.ncbi.nlm.nih.gov/pubmed/22818015
http://dx.doi.org/10.2165/11635490-000000000-00000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590411/
https://www.ncbi.nlm.nih.gov/pubmed/22818015
http://dx.doi.org/10.2165/11635490-000000000-00000

Ejemplares similares